Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 63

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 63
---
 number of issued and outstanding shares of the combined company immediately following the Closing. As of March 28, 2025, the total amount of Kadimastem options that will be exchanged for NLS options at the Effective Time will be 175,600, which will be exchanged for 492,357 NLS options. All such options have been and shall continue to be owned by current and past officers and employees of Kadimastem, and represent approximately 2.04% of the estimated number of issued and outstanding shares of the combined company immediately following the Closing. Additionally, NLS is required to make payments under a finders agreement of warrants to purchase $500,000 worth of NLS Common Shares with an exercise price per share equal to the price per NLS Common Share on Nasdaq immediately prior to the public announcement of such transaction. For more information, please see “The Merger — NLS’s Background of the Merger.” Q.Who can help answer my questions? With regard to the NLS Meeting, shareholders of NLS who have questions may contact NLS by mail (NLS Pharmaceutics Ltd., Alexander Zwyer, The Circle6, 8058 Zurich, Switzerland) or e -mail(acz@nls -pharma.com). xix SUMMARY OF THE PROXY STATEMENT/PROSPECTUS This summary highlights selected information from this proxy statement/prospectus and does not contain all the information that is important to you. To better understand the proposals to be submitted for a vote at the NLS Meeting, including the proposal to approve the Merger, you should carefully read this entire proxy statement/prospectus, including the Merger Agreement and amendments thereto attached as Annex A to this proxy statement/prospectus as well as the other annexes attached hereto. The Merger Agreement is the legal document that governs the Merger and the other transactions that will be undertaken in connection with the Merger. It is also described in detail in this proxy statement/prospectus in the section entitled “Summary of the Material Terms of the Merger Agreement,” but is qualified by reference to the complete text of the Merger Agreement. The Items in this summary includes a page reference directing you to a more complete description of that topic. See the section entitled “Where You Can Find More Information” beginning on page 243 of this proxy statement/prospectus for more information. The Parties to the Merger NLS NLS is a clinical -stagebiopharmaceutical company focused on the